Literatür Detay Bilgisi
BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first and second line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplantation as the treatment of choice;
Yazarlar : Tomuleasa C, Dima D, Frinc I et al
Yayın : Leuk Lymphoma
Yayın Yılı : 2014
Pubmed Linki : http://www.docguide.com/bcr-abl1-t315i-mutation-negative-prognostic-factor-terminal-phase-chronic-myelogenous-leukemia-treat?tsid=5
Konu : Lösemi
Literatür İçeriği : Abstract The current manuscript supports the hypothesis that the allo-SCT is a viable solution for CML before the acutization of the disease if CR-ABL1 T315I mutation is diagnosed, as this molecular marker can potentially be used as a negative prognostic factor for chemotherapy with both first and second line tyrosine kinase inhibitors.
Konusu Aynı Olan Diğer Materyaller
| Sunumlar | Videolar | Olgu Tartışması |
